When was BioBlocks founded?

BioBlocks was founded in 2000 and raised its 1st funding round 18 years after it was founded.

Where is BioBlocks located?

BioBlocks is headquartered in San Diego, United States. It is registered at San Diego, California.

How many employees does BioBlocks have?

As of Dec 31, 2022, BioBlocks has 3 employees, reflecting a 50% year-over-year decline in headcount.

Is BioBlocks a funded company?

BioBlocks is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Aug 01, 2018.

When was the latest funding round of BioBlocks?

BioBlocks' latest funding was a $***** Grant (prize money) round on Jan 01, 2019, with participation from 1 investor. Its primary sector is Biopharma Outsourcing. In United States, the Biopharma Outsourcing sector has seen $420M in funding in 2026 to date.

Where does BioBlocks rank among its competitors?

BioBlocks ranks 60th amongst 233 active competitors, of which 23 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was ChemLex, which secured $45M in Dec, 2025.

Who are the top competitors of BioBlocks?

BioBlocks' top competitors include Sai Life Sciences, Liverpool ChiroChem and NFIL. Among them, ChemLex secured the most recent funding round in December, 2025.

BioBlocks - 2026 Company Profile, Team, Funding & Competitors

Company Details

Drug discovery CRO providing integrated services from target to clinical trials. The company is a fully integrated CRO providing services to support drug discovery programs. Services span from target discovery through IND filing and managing Phase I-III clinical trials. The company specializes in medicinal chemistry services, lead optimization, custom synthesis, bioanalytical services, bioconjugation, and DMPK. It focuses on areas like ADC synthesis and purification, antibody-drug conjugates, and small molecule synthesis. The company supports research in various disease areas, including cancer treatment, diabetes, and rare diseases, utilizing models like xenograft mouse tumor models. The company offers expertise in pharmacokinetics, pharmacodynamics, and clinical trial management.

Website: www.bioblocks.com/
Email ID: *****@bioblocks.com
Phone Number: +1 **********
Registered Address: San Diego, California

Key Metrics

Founded Year

2000

Location

San Diego, United States

Stage

Acquired

Latest Funding Round

Grant (prize money), Jan 01, 2019, $*****

Investors

EIC Fund & 1 more

Ranked

60^th among 233 active competitors

Employee Count

3 as on Dec 31, 2022

Similar Companies

Sai Life Sciences & 270 more

Exit Details

Acquired by Genesis Biotechnology Group (Oct 07, 2021)

View BioBlocks' full profile

BioBlocks is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BIOBLOCKS, INC. CIN: 43518070 , United States, Active	Dec 31, 1999	-	3 (As on Dec 31, 2019)	-

BioBlocks got acquired by Genesis Biotechnology Group on Oct 07, 2021.

Click here to take a look at BioBlocks's acquisition in detail

BioBlocks has raised funding over 2 rounds. Its first funding round was on Aug 01, 2018. Its latest funding round was a Grant (prize money) round on Jan 01, 2019 for $*****. 1 investor participated in its latest round. BioBlocks has 2 institutional investors.

Here is the list of recent funding rounds of BioBlocks:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 01, 2019	7953831	Grant (prize money)	2022864	8817280	5527237	6432210
Aug 01, 2018	3887905	Grant (prize money)	9378602	6751292	7528076	Europa

Access funding benchmarks and valuations. Sign up today!

View details of BioBlocks's funding rounds and investors

The founders of BioBlocks is Peter Pallai.

Here are the details of BioBlocks' key team members:

Peter Pallai: Founder & CEO of BioBlocks.
Contact Info: 1 email address

View details of BioBlocks's Founder profiles and Board Members

BioBlocks' employee count trend

BioBlocks has 3 employees as of Dec 22. The total employee count is 50.0% lower than what it was in Dec 21. Here is BioBlocks's employee count trend over the years:

Uncover BioBlocks' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BioBlocks include Sai Life Sciences, Liverpool ChiroChem and NFIL. Here is the list of Top 10 competitors of BioBlocks, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sai Life Sciences 1999, Hyderabad (India), Public	Provider of drug discovery, developing, and manufacturing of complex small molecules	$108M	Sequoia Capital, HBM Healthcare Investments ... & 122 others	66/100
2nd	Liverpool ChiroChem 2014, Liverpool (United Kingdom), Acquired	Small organic molecule supplier for biotech/pharmaceutical R&D	$11.1M	Praetura Ventures, Northern Powerhouse Investment Fund ... & 4 others	51/100
3rd	NFIL 1967, Mumbai (India), Public	CRAMS company specialising in the custom chemical synthesis and manufacturing of fluorinated compounds	-	-	51/100
4th	GL Chemtec International 2002, Oakville (Canada), Acquired	Discovery stage CRO specializing in custom synthesis of fine chemicals and intermediates	-	-	51/100
5th	Bioduro 2005, San Diego (United States), Acquired	Global CRDMO providing integrated drug discovery, development, and manufacturing services	-	BridgeWest Group	49/100
6th	IRBM 2010, Pomezia (Italy), Funding Raised	Integrated drug discovery and preclinical development service provider	-	BioVaria, Europa	48/100
7th	Medicilon 2004, Pudong (China), Funding Raised	Integrated drug discovery and preclinical development services	-	Spinnotec, Fortune Capital & 1 others	48/100
8th	ChemLex Shanghai (China), Series B	Provider of consulting services in the field of chemical research and development through artificial intelligence chemical synthesis	$71M	LYFE Capital, Qiming Venture Partners & 3 others	46/100
9th	New Iridium 2016, Boulder (United States), Seed	Manufacturer of phenoxazine and dihydrophenazine	$2.65M	Radicle, CIRI Ventures & 6 others	45/100
10th	Alzheimer's Drug Discovery 1998, New York City (United States), Funding Raised	Foundation aims to discover drugs to prevent, treat, and cure alzheimer's disease	-	HHS	45/100
60th	BioBlocks 2000, San Diego (United States), Acquired	Drug discovery CRO providing integrated services from target to clinical trials	-	EIC Fund, Europa	28/100